与二肽基肽酶IV药理抑制相关的复发性血管性水肿
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV.
作者信息
Hermanrud Thorbjørn, Bygum Anette, Rasmussen Eva Rye
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
Dermatology and Allergy Center, University Hospital of Odense, Odense, Denmark.
出版信息
BMJ Case Rep. 2017 Jan 10;2017:bcr2016217802. doi: 10.1136/bcr-2016-217802.
Abstract
Angioedema (AE) of the upper airways is a severe and potentially life-threatening condition. The incidence has been increasing in the past two decades, primarily due to increased use of medications inhibiting the degradation of vasoactive peptides. Acquired angioedema related to angiotensin-converting enzyme inhibitors (ACEI-AAE) is well known, but other pharmaceutical agents also affect the degradation of bradykinin and substance P. We present a middle-aged man with recurrent episodes of severe AE of the oral cavity, hypopharynx and larynx due to pharmacological inhibition of dipeptidyl peptidase IV.
摘要
上气道血管性水肿（AE）是一种严重且可能危及生命的疾病。在过去二十年中，其发病率一直在上升，主要原因是抑制血管活性肽降解的药物使用增加。与血管紧张素转换酶抑制剂相关的获得性血管性水肿（ACEI - AAE）已广为人知，但其他药物也会影响缓激肽和P物质的降解。我们报告了一名中年男性，由于二肽基肽酶IV受到药物抑制，出现口腔、下咽和喉部反复严重发作的AE。
相似文献
1
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV.与二肽基肽酶IV药理抑制相关的复发性血管性水肿
BMJ Case Rep. 2017 Jan 10;2017:bcr2016217802. doi: 10.1136/bcr-2016-217802.
2
Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?二肽基肽酶-4抑制剂诱发的血管性水肿——一种被忽视的药物不良反应？
Curr Diabetes Rev. 2018;14(4):327-333. doi: 10.2174/1573399813666170214113856.
3
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.血管紧张素转换酶抑制剂相关性血管性水肿中的二肽基肽酶IV
Hypertension. 2008 Jan;51(1):141-7. doi: 10.1161/HYPERTENSIONAHA.107.096552. Epub 2007 Nov 19.
4
Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report.药物诱导的血管紧张素转换酶和二肽基肽酶4抑制导致几乎治疗抵抗性的缓激肽诱导的血管性水肿：一例报告
Am J Case Rep. 2017 May 25;18:576-579. doi: 10.12659/ajcr.901960.
5
[Drug induced angioedema (ACE-inhibitors and other)].[药物性血管性水肿（血管紧张素转换酶抑制剂及其他）]
Presse Med. 2015 Jan;44(1):43-7. doi: 10.1016/j.lpm.2014.07.019. Epub 2014 Dec 12.
6
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.血管紧张素转换酶和二肽基肽酶IV抑制剂：血管性水肿风险增加。
Hypertension. 2009 Sep;54(3):468-70. doi: 10.1161/HYPERTENSIONAHA.109.135244. Epub 2009 Jul 6.
7
Bradykinin Metabolism and Drug-Induced Angioedema.缓激肽代谢与药物性血管性水肿。
Int J Mol Sci. 2023 Jul 19;24(14):11649. doi: 10.3390/ijms241411649.
8
Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.使用二肽基肽酶-IV抑制剂与血管紧张素转换酶抑制剂相关血管性水肿风险增加有关。
Hypertension. 2009 Sep;54(3):516-23. doi: 10.1161/HYPERTENSIONAHA.109.134197. Epub 2009 Jul 6.
9
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.血管紧张素转换酶抑制剂和血管紧张素II受体拮抗剂。
Arch Otolaryngol Head Neck Surg. 2004 Dec;130(12):1416-9. doi: 10.1001/archotol.130.12.1416.
10
Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates.用凝血酶原复合物浓缩物治疗由二肽基肽酶-4抑制剂和血管紧张素-I转换酶抑制剂引发的危及生命的喉缓激肽血管性水肿。
Br J Anaesth. 2012 Nov;109(5):827-9. doi: 10.1093/bja/aes371.
引用本文的文献
1
Bradykinin-Mediated Angioedema Induced by Drugs.药物诱导的缓激肽介导的血管性水肿
J Clin Med. 2025 Aug 12;14(16):5712. doi: 10.3390/jcm14165712.
2
Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses.二肽基肽酶-4抑制剂与作用于肾素-血管紧张素-醛固酮系统的药物相互作用导致血管性水肿的风险：一项使用不成比例性分析和相互作用分析的药物警戒评估
Diabetol Metab Syndr. 2025 Jan 7;17(1):7. doi: 10.1186/s13098-024-01570-y.
3
6-(Arylaminomethyl) Isoquinolines as Enzyme Inhibitors and Their Preparation: A Patent Highlight of Factor XIIa Inhibitors.作为酶抑制剂的6-（芳基氨基甲基）异喹啉及其制备：凝血因子XIIa抑制剂的专利亮点
Cardiovasc Hematol Agents Med Chem. 2023;21(3):243-249. doi: 10.2174/1871525721666230126114224.
4
Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS).使用 FDA 不良事件报告系统（FAERS）进行的二肽基肽酶-4 抑制剂与血管性水肿相关性的药物警戒研究。
Sci Rep. 2022 Jul 30;12(1):13122. doi: 10.1038/s41598-022-17366-x.
5
Angioedema associated with dipeptidyl peptidase-IV inhibitors.与二肽基肽酶-IV抑制剂相关的血管性水肿
Clin Mol Allergy. 2021 Dec 6;19(1):24. doi: 10.1186/s12948-021-00164-7.
本文引用的文献
1
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.神经肽Y是成纤维细胞活化蛋白的生理底物：血浆中的酶动力学以及Y2R和Y5R在人类肝硬化和肝细胞癌中的表达
Peptides. 2016 Jan;75:80-95. doi: 10.1016/j.peptides.2015.11.004. Epub 2015 Nov 24.
2
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.恩格列净与利格列汀联合治疗2型糖尿病患者
Expert Opin Pharmacother. 2015;16(18):2819-33. doi: 10.1517/14656566.2015.1114098. Epub 2015 Nov 19.
3
World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base.世界过敏组织过敏反应指南：基于证据的 2013 年更新。
Int Arch Allergy Immunol. 2013;162(3):193-204. doi: 10.1159/000354543. Epub 2013 Sep 5.
4
Angioedema induced by angiotensin-converting enzyme inhibitors.血管性水肿由血管紧张素转换酶抑制剂引起。
Curr Opin Allergy Clin Immunol. 2013 Aug;13(4):337-44. doi: 10.1097/ACI.0b013e328362b835.
5
Angioedema--assessment and treatment.血管性水肿——评估与治疗
Tidsskr Nor Laegeforen. 2012 Nov 12;132(21):2391-5. doi: 10.4045/tidsskr.12.0470.
6
Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates.用凝血酶原复合物浓缩物治疗由二肽基肽酶-4抑制剂和血管紧张素-I转换酶抑制剂引发的危及生命的喉缓激肽血管性水肿。
Br J Anaesth. 2012 Nov;109(5):827-9. doi: 10.1093/bja/aes371.
7
Increasing rate of angiotensin-converting enzyme inhibitor-related upper airway angio-oedema.血管紧张素转换酶抑制剂相关的上气道血管性水肿发生率增加。
Dan Med J. 2012 Jun;59(6):A4449.
8
Angiotensin-converting enzyme inhibitors and angioedema.血管紧张素转化酶抑制剂与血管性水肿。
Allergy Asthma Immunol Res. 2010 Jul;2(3):195-8. doi: 10.4168/aair.2010.2.3.195. Epub 2010 May 6.
9
Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.使用二肽基肽酶-IV抑制剂与血管紧张素转换酶抑制剂相关血管性水肿风险增加有关。
Hypertension. 2009 Sep;54(3):516-23. doi: 10.1161/HYPERTENSIONAHA.109.134197. Epub 2009 Jul 6.
10
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.美国开始使用血管紧张素转换酶抑制剂的退伍军人中血管性水肿的发病率。
Hypertension. 2008 Jun;51(6):1624-30. doi: 10.1161/HYPERTENSIONAHA.108.110270. Epub 2008 Apr 14.
Zotero 插件